+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriasis Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery

  • ID: 4852470
  • Report
  • September 2020
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Dr.Reddy's Laboratories
  • Janssen Biotech Inc.
  • Novartis
Psoriasis Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global psoriasis drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the psoriasis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? the Psoriasis Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) by Drug class: Interleukin Inhibitors; Corticosteroids; Anti-Inflammatory; Tumor Necrosis Factor Inhibitor
2) by Distribution Channel: Hospitals; Retail Pharmacies; E-Commerce
3) by Drug Types: Small molecules; Biologics
4) by Route of Administration: Oral; Tropical; Injectable
5) by Disease Indication: Plaque Psoriasis; Nail Psoriasis; Guttate Psoriasis; Pustular Psoriasis; Erythrodermic Psoriasis

Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Novartis; Eli Lilly and Company.; Celgene Corporation

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Dr.Reddy's Laboratories
  • Janssen Biotech Inc.
  • Novartis
1. Executive Summary

2. Psoriasis Drugs Market Characteristics

3. Psoriasis Drugs Market Size And Growth
3.1. Global Psoriasis Drugs Historic Market, 2015-2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Psoriasis Drugs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Psoriasis Drugs Market Segmentation
4.1. Global Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Interleukin Inhibitors
  • Corticosteroids
  • Anti-Inflammatory
  • Tumor Necrosis Factor Inhibitor
4.2. Global Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospitals
  • Retail Pharmacies
  • E-commerce
4.3. Global Psoriasis Drugs Market, Segmentation By Drug Types, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Small Molecules
  • Biologics
4.4. Global Psoriasis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oral
  • Tropical
  • Injectable
4.5. Global Psoriasis Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Plaque Psoriasis
  • Nail Psoriasis
  • Guttate Psoriasis
  • Pustular Psoriasis
  • Erythrodermic Psoriasis
5. Psoriasis Drugs Market Regional And Country Analysis
5.1. Global Psoriasis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Psoriasis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Psoriasis Drugs Market
6.1. Asia-Pacific Psoriasis Drugs Market Overview
6.2. Asia-Pacific Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Psoriasis Drugs Market
7.1. China Psoriasis Drugs Market Overview
7.2. China Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Psoriasis Drugs Market
8.1. India Psoriasis Drugs Market Overview
8.2. India Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Psoriasis Drugs Market
9.1. Japan Psoriasis Drugs Market Overview
9.2. Japan Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Psoriasis Drugs Market
10.1. Australia Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Psoriasis Drugs Market
11.1. Indonesia Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Psoriasis Drugs Market
12.1. South Korea Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Psoriasis Drugs Market
13.1. Western Europe Psoriasis Drugs Market Overview
13.2. Western Europe Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Psoriasis Drugs Market
14.1. UK Psoriasis Drugs Market Overview
14.2. UK Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Psoriasis Drugs Market
15.1. Germany Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Psoriasis Drugs Market
16.4. France Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Psoriasis Drugs Market
17.1. Eastern Europe Psoriasis Drugs Market Overview
17.2. Eastern Europe Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Psoriasis Drugs Market
18.1. Russia Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Psoriasis Drugs Market
19.1. North America Psoriasis Drugs Market Overview
19.2. North America Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Psoriasis Drugs Market
20.1. USA Psoriasis Drugs Market Overview
20.2. USA Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Psoriasis Drugs Market
21.1. South America Psoriasis Drugs Market Overview
21.2. South America Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Psoriasis Drugs Market
22.1. Brazil Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Psoriasis Drugs Market
23.1. Middle East Psoriasis Drugs Market Overview
23.2. Middle East Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Psoriasis Drugs Market
24.1. Africa Psoriasis Drugs Market Overview
24.2. Africa Psoriasis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Psoriasis Drugs Market Competitive Landscape And Company Profiles
25.1. Psoriasis Drugs Market Competitive Landscape
25.2. Psoriasis Drugs Market Company Profiles
25.2.1. AbbVie Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Pfizer Inc.
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Novartis
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Eli Lilly and Company.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Celgene Corporation
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Psoriasis Drugs Market

27. Psoriasis Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Psoriasis Drugs Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. About the Publisher
30.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Dr.Reddy's Laboratories
  • Janssen Biotech Inc.
  • Novartis
Major players in the psoriasis drugs market are AbbVie Inc., Pfizer Inc., Novartis, Eli Lilly and Company and Celgene Corporation.

The global psoriasis drugs market is expected to decline from $16.2 billion in 2019 to $14.4 billion in 2020 at a compound annual growth rate (CAGR) of -10.8%. The decline is mainly because of drop in sales due to the lockdown measures to contain COVID-19 spread. Apart from restricting non-emergency medical services, new rules of the governments across the globe has forced many companies in the dermatology drug market to halt their business operations which has impacted the market growth. The market is then expected to recover and grow at a CAGR of 9.5% from 2021 and reach $24.4 billion in 2023.

The psoriasis drugs market consists of sales of psoriasis drugs. Psoriasis is a persistent skin disorder which causes distress and pain through patches of abnormal skin. Psoriasis can be caused due to injuries to skin, medications, genetics, infection, diet, weather, etc. The drugs vary depending on the severity of the infection and provide relief from infections. Examples of drugs in the psoriasis market include Clobetasol (Temovate), triamcinolone (Aristocort), fluocinolone (Synalar), and betamethasone (Diprolene).

North America was the largest region in the psoriasis drugs market in 2018. This region is expected to remain the largest during the next five years. The psoriasis drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The process of approval of psoriasis drugs is becoming easier globally. This is evident from the increasing approvals of drugs for psoriasis in the recent years. Some of the examples include the first regulatory approval of SKYRIZI™ (risankizumab) for the treatment of plaque psoriasis in Japan in 2019, and the approval of a new treatment for plaque psoriasis in Europe in 2018. Hence, the increasing ease of drug approvals is expected to drive the psoriasis drugs market in the coming years.

The high cost of psoriasis therapy is a restraint for the psoriasis market. According to a study conducted by JAMA Dermatology in 2019, the typical psoriasis treatments with biologics are very costly, ranging between $10,000 and $25,000 per year. The high cost is because patent protections are preventing many alternative drugs.

Combination therapy is an emerging trend in the psoriasis market. Combination therapy is an f treatment that combines two different psoriasis treatments at the same time. When two drugs with different mechanisms of action are combined (combination therapy), the effect is greater than that obtained by monotherapy (treatment with a single drug). Studies suggest that combination therapy eases psoriasis symptoms more effectively than a single therapy and has lesser side effects. An example of combination therapy for the treatment of active psoriatic arthritis (PsA) is taltz (ixekizumab) with methotrexate developed by Eli Lilly and Company.

The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to immune system, genetics and environment. The rise in psoriasis patients in the past few years can be mainly attributed to climate change, stress and unhealthy lifestyle. According to the World Health Organization (WHO), psoriasis had affected at least 100 million individuals worldwide in 2016.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Pfizer Inc.
  • Novartis
  • Eli Lilly and Company.
  • Celgene Corporation
  • Johnson & Johnson
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co Inc.
  • Janssen Biotech Inc.
  • Takeda Pharmaceutical Company Limited
  • Stiefel Laboratories Inc.
  • AstraZeneca
  • UCB
  • Sun Pharmaceutical Industries Ltd
  • Forward Pharma
  • Almirall
  • Valeant Pharmaceuticals
  • Biogen Idec
  • Biocon
  • Celltrion Inc.
  • Dr.Reddy's Laboratories
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll